Document Type

Oral Presentation

Location

Oxford Convention Center, 102 Ed Perry Boulevard Oxford, MS 38655

Event Website

https://oxfordicsb.org/

Start Date

18-4-2024 11:15 AM

End Date

18-4-2024 11:30 AM

Description

Metabolic enzyme and/or transporter-mediated pharmacokinetic (PK) changes in a drug caused by concomitant herbal products have been a primary issue of herb and drug interactions (HDIs), because PK changes of a drug may result in the alternation of efficacy and toxicity. Studies on HDIs have been carried out by predictive in vitro and in vivo preclinical studies, and clinical trials. Nevertheless, the discrepancies between predictive data and the clinical significance on HDIs still exist, and different reports of HDIs add to rather than clarify the confusion regarding the use of herbal products and drug combinations. Here, the underlying mechanisms causing PK-based HDIs mainly focusing on the “reverse pharmacokinetics (e.g., systemic exposure and local tissue distributions)” are summarized. In addition, dose and treatment period effects as challenging issues in study designs and interpretations of HDI evaluation should be also considered. Several examples of HDIs are provided to describe these multifaced factors to be considered in the interpretation of HDIs.

Comments

This research was supported by the National Research Foundation of the Republic of Korea (NRF) in the Korean government (MSIT) [grant numbers: NRF-2016R1C1B10`0849, NRF-2018R1A5A2023127, NRF-2021R1A2C1094462, and RS-2023-00261934].

Publication Date

April 2024

Accessibility Status

Searchable text

Share

COinS
 
Apr 18th, 11:15 AM Apr 18th, 11:30 AM

Multifaced factors to cause conflicting outcomes in drug-herb interactions mainly focusing on reverse pharmacokinetics

Oxford Convention Center, 102 Ed Perry Boulevard Oxford, MS 38655

Metabolic enzyme and/or transporter-mediated pharmacokinetic (PK) changes in a drug caused by concomitant herbal products have been a primary issue of herb and drug interactions (HDIs), because PK changes of a drug may result in the alternation of efficacy and toxicity. Studies on HDIs have been carried out by predictive in vitro and in vivo preclinical studies, and clinical trials. Nevertheless, the discrepancies between predictive data and the clinical significance on HDIs still exist, and different reports of HDIs add to rather than clarify the confusion regarding the use of herbal products and drug combinations. Here, the underlying mechanisms causing PK-based HDIs mainly focusing on the “reverse pharmacokinetics (e.g., systemic exposure and local tissue distributions)” are summarized. In addition, dose and treatment period effects as challenging issues in study designs and interpretations of HDI evaluation should be also considered. Several examples of HDIs are provided to describe these multifaced factors to be considered in the interpretation of HDIs.

https://egrove.olemiss.edu/icsb/2024_ICSB/Schedule/26

 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.